Rotterdam Study

Rotterdam Study
Name	Rotterdam Study
Established	1990
Location	Rotterdam
Focus	Cohort study of chronic diseases in the elderly
Founders	Erasmus University Rotterdam

Rotterdam Study The Rotterdam Study is a large prospective population-based cohort initiated in 1990 in Rotterdam to investigate determinants and risk factors for chronic diseases in middle-aged and elderly populations. It links clinical examinations, imaging, genomics, and registries to study outcomes such as cardiovascular disease, dementia, ophthalmic disorders, and musculoskeletal conditions. The project is embedded in academic, clinical, and public-health networks including Erasmus University Rotterdam, the University Medical Center Rotterdam, and international consortia such as CHARGE Consortium and Global Burden of Disease collaborators.

History

The study was conceived at Erasmus University Rotterdam under leadership from investigators affiliated with Erasmus MC and expanded through successive waves in 1990, 2000, and 2006 to increase sample size and age range. Key historical milestones include the addition of neuroimaging suites inspired by work at Massachusetts General Hospital, the integration of genome-wide association strategies following success at the Wellcome Trust and the adoption of harmonized phenotyping approaches mirrored in the Framingham Heart Study and UK Biobank. Governance adaptations occurred in response to European data-protection developments after the enactment of the General Data Protection Regulation.

Study Design and Methods

The cohort employs prospective longitudinal design with repeated baseline and follow-up examinations, typical of population cohorts like the Cardiovascular Health Study and the Rotterdam Study's contemporaries at Johns Hopkins University and University of California, San Francisco. Recruitment targeted inhabitants of defined districts in Rotterdam aged 55 years and older, with sampling frames derived from municipal registries maintained by the Municipality of Rotterdam. Methodological staples include standardized clinical assessments influenced by protocols from the World Health Organization, centralized biobanking reminiscent of Biobank Japan, and linkage to national registries such as those at the Dutch National Institute for Public Health and the Environment.

Major Findings and Contributions

The project produced influential evidence on risk factors for stroke, myocardial infarction, and heart failure that have been cited alongside landmark findings from Framingham Heart Study and ARIC Study. It elucidated genetic and environmental contributors to Alzheimer's disease, complementing findings from Alzheimer's Disease Neuroimaging Initiative and International Genomics of Alzheimer's Project. Ophthalmic research from the cohort advanced understanding of age-related macular degeneration and glaucoma, intersecting with work at the NEI and European Society of Retina Specialists. Musculoskeletal outputs have informed fracture risk modeling used by guideline groups like those convened by World Health Organization and regional regulators such as European Medicines Agency.

Data Collection and Measurements

Data modalities include structured interviews and questionnaires adapted from instruments used by National Institutes of Health, physical examinations influenced by standards at the American Heart Association, electrocardiography protocols akin to those at Mayo Clinic, imaging pipelines comparable to UK Biobank and Alzheimer's Disease Neuroimaging Initiative, and genotyping arrays following designs from the Wellcome Trust Case Control Consortium. Biospecimens are stored in a centralized biorepository with procedures paralleling those at European Molecular Biology Laboratory and linked to municipal and national registries such as databases at the Dutch Hospital Data and the Central Bureau of Statistics (Netherlands).

Governance, Funding, and Collaborations

Governance is overseen by academic leadership from Erasmus University Rotterdam and clinical partners at Erasmus MC, with advisory input from international experts drawn from institutions such as Harvard School of Public Health, Karolinska Institutet, and Imperial College London. Funding sources have included national agencies like the Netherlands Organisation for Health Research and Development and European frameworks such as Horizon 2020, alongside philanthropic support modeled on initiatives by the Gates Foundation and collaborative grants with consortia including the CHARGE Consortium and the International HapMap Project.

Impact on Public Health and Policy

Findings have informed clinical risk prediction tools referenced by guideline committees at the European Society of Cardiology and have contributed data used in burden estimates compiled by the Global Burden of Disease collaborators. The study’s evidence on dementia, cardiovascular disease, and ocular pathology has been cited in policy discussions at municipal and national levels including advisory bodies linked to the Ministry of Health, Welfare and Sport (Netherlands), and in guideline development by international organizations such as the World Health Organization.

Category:Cohort studies Category:Epidemiology